Enpatoran Clinical Trials (2026): 6 Studies for Healthy & Cutaneous Lupus Erythematosus (CLE)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
6 Enpatoran clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Healthy & Cutaneous Lupus Erythematosus (CLE)) and 941 total planned enrollment. 2 Phase 3 Enpatoran trials and 1 Phase 2 are listed. 2 Enpatoran clinical trials are actively recruiting at 9 U.S. sites across 6 states. Most recent activity: NCT07355218 (May 2029).
Where to Participate: All Enpatoran Trial Sites in the U.S. (9 sites across 6 states)
Every actively recruiting Enpatorantrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Dermatology Research Associates - 300204025 | Los Angeles90045 | NCT07332481 | Map |
| CA | Inland Rheumatology Clinical Trials, Inc. | Upland91786 | NCT07355218 | Map |
| FL | Omega Research Debary, LLC | DeBary32713 | NCT07355218 | Map |
| FL | Bolanos Clinical Research | Pembroke Pines33026 | NCT07355218 | Map |
| GA | Emory University School of Medicine | Atlanta30303 | NCT07332481 | Map |
| IN | Dawes Fretzin Clinical Research Group, LLC | Indianapolis46250 | NCT07355218 | Map |
| MI | Revival Research Institute, LLC | Troy48084 | NCT07332481 | Map |
| TX | Allen Arthritis | Allen75013 | NCT07332481 | Map |
| TX | Arthritis and Rheumatology Research Institute PLLC | Allen75013 | NCT07332481 | Map |
Enpatoran clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 3 | 3 | |
| P2 | 1 | 1 | |
| P3 | 2 | 2 |
Recruiting Enpatoran clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07355218 | ELOWEN-2A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) | P3 | Systematic Lupus Erythematosus | 202 | Apr 2026 |
| NCT07332481 | ELOWEN-1A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease | P3 | Systemic Lupus Erythematosus (SLE) | 202 | Mar 2026 |
Enpatoran clinical trials by indication
Healthy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06589726 | — | P1 | completed | A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants |
| NCT05110027 | — | P1 | completed | Enpatoran Human Mass Balance and Absolute Bioavailability Study |
Systematic Lupus Erythematosus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07355218 | ELOWEN-2 | P3 | recruiting | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) |
Systemic Lupus Erythematosus (SLE) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07332481 | ELOWEN-1 | P3 | recruiting | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease |
Renal Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06589713 | — | P1 | completed | Effect of Renal Impairment on Enpatoran Pharmacokinetics |
Systemic Lupus Erythematosus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05162586 | WILLOW | P2 | completed | The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) |
Enpatoran pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ELOWEN-2 | NCT07355218 | P3 | recruiting | Systematic Lupus Erythematosus | 202 | — |
| ELOWEN-1 | NCT07332481 | P3 | recruiting | Systemic Lupus Erythematosus (SLE) | 202 | — |
| WILLOW | NCT05162586 | P2 | completed | Systemic Lupus Erythematosus | 456 | PMID 42107375 |
All Enpatoran trials (6)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07355218 | ELOWEN-2 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) | P3 | recruiting | 202 | EMD Serono Research & Development Institute, Inc. | Apr 2026 |
| NCT07332481 | ELOWEN-1 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease | P3 | recruiting | 202 | EMD Serono Research & Development Institute, Inc. | Mar 2026 |
| NCT06589713 | Effect of Renal Impairment on Enpatoran Pharmacokinetics | P1 | completed | 34 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Sep 2024 | |
| NCT06589726 | A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants | P1 | completed | 40 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Sep 2024 | |
| NCT05162586 | WILLOW | The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) | P2 | completed | 456 | EMD Serono Research & Development Institute, Inc. | Mar 2022 |
| NCT05110027 | Enpatoran Human Mass Balance and Absolute Bioavailability Study | P1 | completed | 7 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Nov 2021 |
Enpatoran clinical trials: frequently asked questions
- How many Enpatoran clinical trials are there?
- 6 Enpatoran clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 4 are marked completed.
- Are Enpatoran clinical trials recruiting in 2026?
- Yes — 2 Enpatoran trials are actively recruiting in 2026, with 9 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Enpatoran being studied for?
- Enpatoran is being studied for Healthy, Cutaneous Lupus Erythematosus (CLE), Cutaneous Lupus Erythematosus, Systematic Lupus Erythematosus, Systemic Lupus Erythematosus and 2 more. The trials are grouped by indication on this page.
- What phase is Enpatoran in?
- Enpatoran clinical trials span 2 Phase 3, 1 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Enpatoran clinical trials?
- The lead sponsor across the most Enpatoran trials is EMD Serono Research & Development Institute, Inc., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Enpatoranas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: